A Phase Ⅰb Study of Remimazolam Tosylate in Healthy Volunteers

• Study the Pharmacokinetics/Pharmacodynamics of Remimazolam Tosylate in healthy volunteers after loading/maintenance dose regimen.
• Study the reversal effect and time required of Flumazepine on Rimazolam'effect.
• Study the Safety of Remimazolam Tosylate in healthy volunteers after loading/maintenance dose regimen.

Inclusion criteria

• Aged ≥18 and ≤55 years.
• Weight range 50 to 100 kg and body mass index (BMI) 18 to 26 kg/m2.
• Willing and able to comply with the requirements of the protocol.
• Provide written informed consent to participate in the study.

Exclusion criteria

• Abnormal results of physical or laboratory examination with clinical significance
• With a history of laboratory results that show the presence of hepatitis B surface antigen (HBs Ag), hepatitis C antibody (HCV Ab), or human immunodeficiency virus (HIV).
• With evidence of uncontrolled renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction, in the opinion of the investigator or medical monitor.
• Subject with clinically significant abnormalities in baseline 12-lead electrocardiogram (ECG) or vital signs（SBP <90 mmHg or >140 mmHg，DBP <50 mmHg or >90 mmHg；Hr <50 bpm or >100 bpm；SpO2 <95%）.
• Has a known sensitivity to benzodiazepines, flumazenil, or anesthetic agents, or a medical condition such that these agents are contraindicated.
• Receipt of other medication within 14 days of the first study day.
• Blood donation greater than 200 ml or participation in a clinical study of an unlicensed drug in the previous 3 months.
• History of smoking or alcohol abuse within 6 months of screening.
• History of grapefruit juice or any other foods affect the activity of cytochrome P450 3A4（CYP3A4） within 7 days of screening.
• Pregnant,lactating.
• Mallampati score ≥3.
• Patients who in the opinion of the investigator may not be able to comply with the requirements of the study are not eligible